|
Volumn 195, Issue 9, 2002, Pages 1207-1213
|
The ligand-binding domain of CD22 is needed for inhibition of the B cell receptor signal, as demonstrated by a novel human CD22-specific inhibitor compound
|
Author keywords
B lymphocytes; Ca2+ flux; CD22; Sialic acid; Siglecs
|
Indexed keywords
B LYMPHOCYTE RECEPTOR;
CD22 ANTIGEN;
IMMUNOGLOBULIN M;
SIALIC ACID;
ANIMAL CELL;
ARTICLE;
B LYMPHOCYTE;
BINDING AFFINITY;
CALCIUM CELL LEVEL;
CALCIUM MOBILIZATION;
CALCIUM TRANSPORT;
CELL STIMULATION;
CONTROLLED STUDY;
DAUDI CELL;
HUMAN;
HUMAN CELL;
LIGAND BINDING;
MOLECULAR WEIGHT;
MOUSE;
NONHUMAN;
PRIORITY JOURNAL;
PROTEIN DOMAIN;
PROTEIN PHOSPHORYLATION;
SIGNAL TRANSDUCTION;
ANIMALS;
ANTIGENS, CD;
ANTIGENS, CD22;
ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE;
BINDING SITES;
CELL ADHESION MOLECULES;
CELL LINE;
HUMANS;
IMMUNOGLOBULIN FC FRAGMENTS;
KINETICS;
LECTINS;
LIGANDS;
MICE;
PROTEIN-TYROSINE-PHOSPHATASE;
RECEPTORS, ANTIGEN, B-CELL;
RECOMBINANT FUSION PROTEINS;
SRC HOMOLOGY DOMAINS;
TUMOR CELLS, CULTURED;
|
EID: 0037029667
PISSN: 00221007
EISSN: None
Source Type: Journal
DOI: 10.1084/jem.20011783 Document Type: Article |
Times cited : (164)
|
References (28)
|